Growth hormone treatment does not augment the anti-diabetic effects of liraglutide in UCD-T2DM rats.

ABSTRACT:

Introduction

The incretin hormone glucagon-like peptide-1 (GLP-1) slows gastric emptying, increases satiety and enhances insulin secretion. GLP-1 receptor agonists, such as liraglutide, are used therapeutically in humans to improve glycaemic control and delay the onset of type 2 diabetes mellitus (T2DM). In UCD-T2DM rats, a model of polygenic obesity and insulin resistance, we have previously reported that daily liraglutide administration delayed diabetes onset by >4 months. Growth hormone (GH) may exert anti-diabetic effects, including increasing β-cell mass and insulin secretion, while disrupting GH signalling in mice reduces both the size and number of pancreatic islets. We therefore hypothesized that GH supplementation would augment liraglutide's anti-diabetic effects.

Metho

SUBMITTER: Swarbrick MM 

PROVIDER: S-EPMC9836246 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature